Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer

David R. Fogelman,Holly M. Holmes,Khalil Mohammed,Matthew Harold Katz,Carla M. Prado,Jessica Lieffers,Naveen Garg,Gauri R. Varadhachary,Rachna T. Shroff,Michael J. Overman,Christopher R. Garrett,Robert A. Wolff,Milind Javle

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer

2014

David R. Fogelman
Holly M. Holmes
Khalil Mohammed
Matthew Harold Katz
Carla M. Prado
Jessica Lieffers
Naveen Garg
Gauri R. Varadhachary
Rachna T. Shroff
Michael J. Overman
Christopher R. Garrett
Robert A. Wolff
Milind Javle

Background IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown.

Keywords:

Pancreatic cancer
Sarcopenia
Growth factor
Endocrinology
Diabetes mellitus
Medicine
Cachexia
Adenocarcinoma
Internal medicine
Molecular medicine
Clinical nutrition

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations